Soligenix: 3/17/2022 - COVID-19 Vaccine, CiVax, Boosts Neutralizing Activity Against SARS-CoV-2, Including Delta And Omicron
7:34 am ET March 17, 2022.
CiVax™ booster vaccine administered seven months after primary vaccination with COVID-19 adenovirus vaccine shows rapid enhancement of neutralizing antibody responses in non-human primates
Neutralizing antibodies against Delta and original strain increased by up to 27-fold within one week and up to 243-fold within three weeks
Omicron neutralizing antibody levels were undetectable prior to booster vaccination, and attained presumed protective levels within one week of vaccination.
GLTA
Market Data 
Markets 
AI
